Display options
Cite
Oyman A, Basak M, Odabas H, et al. Characteristics and clinical outcome of pT1a-b node-negative breast cancer. North Clin Istanb. 2021;8(2):124-129doi: 10.14744/nci.2020.06332.
Oyman, A., Basak, M., Odabas, H., & Ozcelik, M. (2021). Characteristics and clinical outcome of pT1a-b node-negative breast cancer. Northern clinics of Istanbul, 8(2), 124-129. https://doi.org/10.14744/nci.2020.06332
Oyman, Abdilkerim, et al. "Characteristics and clinical outcome of pT1a-b node-negative breast cancer." Northern clinics of Istanbul vol. 8,2 (2021): 124-129. doi: https://doi.org/10.14744/nci.2020.06332
Oyman A, Basak M, Odabas H, Ozcelik M. Characteristics and clinical outcome of pT1a-b node-negative breast cancer. North Clin Istanb. 2021 Mar 24;8(2):124-129. doi: 10.14744/nci.2020.06332. eCollection 2021. PMID: 33851075; PMCID: PMC8039097.
Copy Download .nbib Format: NLM
Share it on

North Clin Istanb. 2021 Mar 24;8(2):124-129. doi: 10.14744/nci.2020.06332. eCollection 2021.

Characteristics and clinical outcome of pT1a-b node-negative breast cancer.

Northern clinics of Istanbul

Abdilkerim Oyman, Mustafa Basak, Hatice Odabas, Melike Ozcelik

Affiliations

  1. Department of Medical Oncology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.
  2. Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey.

PMID: 33851075 PMCID: PMC8039097 DOI: 10.14744/nci.2020.06332

Abstract

OBJECTIVE: Tumor size, along with other clinicopathological characteristics, has a prognostic role in breast cancer. Recurrence risk tends to rise as tumor size increases. Early T-stage portends a good prognosis. We aimed to investigate the recurrence-free interval rates of T1abN0 group of early breast cancer.

METHODS: Patients diagnosed with pT1a and T1b, lymph node metastasis-negative breast cancer were included in the study. Clinicopathologic characteristics including recurrence, distant metastasis, and final status of the patients were obtained retrospectively from the patient files.

RESULTS: A total of 84 patients included. Twenty-six patients (31%) had T1a and 58 patients (69%) had T1b tumors. The 5-year distant relapse-free survival (DRFS) rate of T1ab tumors was 95.2%. The DRFS rate of T1a tumors was 96.2%, while the rate of T1b tumors was 94.8% (p=0.555). The 5-year RFS rate of T1ab tumors was 90.5%. The RFS rate of T1a tumors was 84.6%, whereas the rate of T1b tumors was 93.1% (p=0.359). The 5-year DRFS rate of hormone receptor positive group was 97%, Her-2 positive group was 81.8%, and triple negative group was 100% (p=0.041). The 5-year RFS rate of the hormone receptor positive group was 97%, Her-2 positive group was 72.7%, and triple negative group was 57.1% (p=0.001).

CONCLUSION: The results of the study provided that both T1a and T1b tumors have a good and similar prognosis.

Copyright: © 2021 by Istanbul Northern Anatolian Association of Public Hospitals.

Keywords: Distant relapse-free survival; T1ab; early breast cancer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

  1. J Clin Oncol. 1993 Nov;11(11):2090-100 - PubMed
  2. Aust N Z J Public Health. 2004 Aug;28(4):312-6 - PubMed
  3. Clin Breast Cancer. 2011 Oct;11(5):325-31 - PubMed
  4. Cancer. 1995 Dec 1;76(11):2266-74 - PubMed
  5. Surg Gynecol Obstet. 1992 Aug;175(2):151-60 - PubMed
  6. Breast Cancer Res Treat. 2011 Jun;127(3):713-20 - PubMed
  7. J Clin Oncol. 1989 Mar;7(3):355-66 - PubMed
  8. BMC Cancer. 2007 Aug 08;7:153 - PubMed
  9. Am J Clin Oncol. 1987 Oct;10(5):396-403 - PubMed
  10. Br J Cancer. 2004 Aug 31;91(5):861-7 - PubMed
  11. Breast Cancer Res Treat. 2010 Feb;119(3):653-61 - PubMed
  12. Cancer. 2012 Jul 1;118(13):3236-43 - PubMed
  13. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  14. Cancer. 2007 Nov 1;110(9):1929-36 - PubMed
  15. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  16. Arch Gynecol Obstet. 2016 Aug;294(2):377-84 - PubMed
  17. BMC Cancer. 2010 Oct 15;10:557 - PubMed
  18. Ann Surg. 1989 Feb;209(2):249-53 - PubMed
  19. N Engl J Med. 2006 Feb 23;354(8):809-20 - PubMed
  20. Clin Cancer Res. 2003 Mar;9(3):923-30 - PubMed
  21. Breast Cancer Res Treat. 2012 Jul;134(1):81-7 - PubMed
  22. N Engl J Med. 2005 Oct 20;353(16):1659-72 - PubMed
  23. Ann Oncol. 2004 Nov;15(11):1633-9 - PubMed
  24. Cancer. 2002 Apr 15;94(8):2160-8 - PubMed
  25. J Natl Cancer Inst. 2001 Jan 17;93(2):112-20 - PubMed
  26. Ann Oncol. 2014 Mar;25(3):623-628 - PubMed

Publication Types